AC-262536
Muscle Growth & Body CompositionAlso known as: AC262536, Accadrine
Mechanism
AC-262536 (Accadrine) is a preclinical SARM developed by Acadia Pharmaceuticals with moderate anabolic activity and good tissue selectivity. It shows approximately 66% of testosterone's muscle-building effect with only 27% of its prostate-stimulating activity in animal models.
Technical detail
AC-262536 is a non-steroidal SARM that binds AR with moderate affinity (Ki ~5 nM) and demonstrates partial agonist activity. In castrated rat models, it achieved 66% of the maximal anabolic effect of testosterone propionate on the levator ani with only 27% of the androgenic effect on seminal vesicles, yielding a selectivity index of approximately 2.45:1. It remains in early preclinical evaluation with no progression to human trials.
Evidence
- moderate
Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator
Piu et al. (2008) — J Steroid Biochem Mol Biol — PMID: 18164613
AC-262536 showed selective androgen receptor activity with favorable anabolic effects in castrated male rats, including levator ani growth and LH suppression, while producing relatively weak prostate and seminal vesicle stimulation versus testosterone. Evidence is animal-only.